6533b838fe1ef96bd12a3b96

RESEARCH PRODUCT

Identification <i>In Silico</i> and <i>In Vitro</i> of Novel Trypanosomicidal Drug-like Compounds

Miriam RolónCrisitan Ochoa PuentesVladimir V. KouznetsovOremia Del Toro-cortésJosé Antonio EscarioFrancisco TorrensConcepción AbadYovani Marrero-ponceAlicia Gómez-barrioMaria Celeste VegaArnold R. Romero BohórquezJuan A. Castillo-garit

subject

DrugVirtual screeningChromatographybiologyChemistrymedia_common.quotation_subjectIn silicobiology.organism_classificationLinear discriminant analysisIn vitromedicineTrypanosoma cruziNifurtimoxmedia_commonmedicine.drug

description

Atom-based bilinear indices and linear discriminant analysis are used to discover novel trypanosomicidal compounds. The obtained linear discriminant analysis-based quantitative structure–activity relationship models, using non-stochastic and stochastic indices, provide accuracies of 89.02% (85.11%) and 89.60% (88.30%) of the chemicals in the training (test) sets, respectively. Later, both models were applied to the virtual screening of 18 in-house synthesized compounds to find new pro-lead antitrypanosomal agents. The in vitro antitrypanosomal activity of this set against epimastigote forms of Trypanosoma cruzi is assayed. Predictions agree with experimental results to a great extent (16/18) of the chemicals. Sixteen compounds show more than 70% of epimastigote inhibition at a concentration 100 μg/mL. In addition, three compounds (CRIS 112, CRIS 140 and CRIS 147) present more than 70% of epimastigote inhibition at a concentration of 10 μg/mL (79.95%, 73.97% and 78.13%, respectively) with low values of cytotoxicity (19.7%, 7.44% and 20.63%, correspondingly).Taking into account all these results, we could say that these three compounds could be optimized in forthcoming works. Even though none of them resulted more active than nifurtimox, the current results constitute a step forward in the search for efficient ways to discover new lead antitrypanosomals.

https://doi.org/10.3390/ecsoc-16-01072